CLINICAL_TRIALS ClinicalTrials.gov record update

Open-Label, Randomized Phase 2 Trial of Ramucirumab in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-Line Treatment of PD-L1 Positive, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (RM-HNSCC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05980000
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:06.333227+00:00
Published At: 2026-03-31T00:00:00+00:00
Record Updated At: 2026-03-31
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Head and Neck Cancer", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Carcinoma", "Metastatic Head-and-neck Squamous-cell Carcinoma", "Metastatic Head and Neck Cancer", "HNSCC"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-31"
protocolSection.identificationModule.nctId: "NCT05980000"
protocolSection.identificationModule.officialTitle: "Open-Label, Randomized Phase 2 Trial of Ramucirumab in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-Line Treatment of PD-L1 Positive, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (RM-HNSCC)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.